AstraZeneca completed the acquisition of TeneoTwo, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, which is currently under evaluation in B-cell non-Hodgkin lymphoma. AstraZeneca will develop TNB-486 as a potential new medicine for B-cell hematologic malignancies.
Financial Considerations
AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m. Under the terms of the agreement, AstraZeneca will make additional contingent R&D-related milestone payments of up to $805m and additional contingent commercial-related milestone payments of up to $360m to TeneoTwo’s former equity holders.
This acquisition did not include the transfer of people or facilities.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!